Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RLYB Rallybio Corp
- Stocks
- Healthcare
- NASDAQ: RLYB
Price (delayed)
$0.5764
Market cap
$23.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.09
Enterprise value
$9.32M
Highlights
RLYB's debt has dropped by 66% year-on-year and by 25% since the previous quarter
The quick ratio has grown by 49% YoY and by 33% from the previous quarter
The equity has declined by 39% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of RLYB
Market
Valuations
Earnings
Shares outstanding
41.61M
Market cap
$23.99M
Enterprise value
$9.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
30.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.99
Revenue
$848,000
Gross profit
$848,000
Operating income
-$50.38M
Net income
-$48.19M
EBIT
-$48.19M
EBITDA
-$48.06M
Free cash flow
-$44.03M
Per share
Balance sheet
Liquidity
EPS
-$1.09
EPS diluted
-$1.09
Free cash flow per share
-$0.98
Book value per share
$1.3
Revenue per share
$0.02
TBVPS
$1.29
Total assets
$57.98M
Total liabilities
$3.91M
Debt
$116,000
Equity
$54.07M
Working capital
$53.47M
Debt to equity
0
Current ratio
14.68
Quick ratio
13.94
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
-5,667.6%
Gross margin
100%
Net margin
-5,682.2%
Operating margin
-5,940.9%
Return on assets
-64.8%
Return on equity
-72.3%
Return on invested capital
-97.8%
Return on capital employed
-89.1%
Return on sales
-5,682.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLYB stock price
How has the Rallybio stock price performed over time
Intraday
69.33%
1 week
74.51%
1 month
45.92%
1 year
-55.66%
YTD
-39.96%
QTD
70.53%
Financial performance
How have Rallybio's revenue and profit performed over time
Revenue
$848,000
Gross profit
$848,000
Operating income
-$50.38M
Net income
-$48.19M
Gross margin
100%
Net margin
-5,682.2%
Rallybio's operating margin has increased by 38% from the previous quarter
Rallybio's net income has increased by 37% YoY and by 17% QoQ
RLYB's operating income is up by 37% year-on-year and by 17% since the previous quarter
RLYB's net margin is up by 37% since the previous quarter
Price vs fundamentals
How does RLYB's price correlate with its fundamentals
Growth
What is Rallybio's growth rate over time
Valuation
What is Rallybio stock price valuation
P/E
N/A
P/B
0.44
P/S
30.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.99
The EPS is up by 42% year-on-year and by 18% since the previous quarter
RLYB's price to book (P/B) is 57% lower than its last 4 quarters average of 0.6
The equity has declined by 39% year-on-year and by 12% since the previous quarter
The stock's price to sales (P/S) is 81% less than its last 4 quarters average of 96.3
RLYB's revenue is up by 33% from the previous quarter
Efficiency
How efficient is Rallybio business performance
The ROS is up by 37% since the previous quarter
The ROIC has declined by 17% year-on-year but it has grown by 3.5% since the previous quarter
RLYB's return on equity is down by 9% year-on-year but it is up by 6% since the previous quarter
Rallybio's return on assets has decreased by 5% YoY but it has increased by 5% QoQ
Dividends
What is RLYB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLYB.
Financial health
How did Rallybio financials performed over time
Rallybio's total liabilities has plunged by 62% YoY and by 39% from the previous quarter
The current ratio has surged by 50% year-on-year and by 35% since the previous quarter
RLYB's debt is 100% smaller than its equity
RLYB's debt has dropped by 66% year-on-year and by 25% since the previous quarter
The equity has declined by 39% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.